Despite increasing numbers of women with HIV worldwide, females are under-represented in clinical trials of antiretrovirals and literature addressing gender differences in clinical outcomes, treatment discontinuation, adverse events and adherence are limited. Most recommendations specific to women in current guidelines relate to pregnant women or women wishing to become pregnant. The purpose of this systematic review is to provide clinicians with an overview of available literature regarding the use of ritonavir-boosted atazanavir (ATV/r) in women.
Methods
The online databases PubMed and EMBASE, HIV-related conference abstracts and reference lists of relevant articles were searched according to predefined terms and limited to items published from 1 October 2007 to 1 October 2012. Updates to conference presentations were checked for substantive journal publication up to 28 November 2013.
Results
Of the 294 initial citations retrieved, manual selection identified 19 relevant publications describing gender-based analyses of ATV/r. Publications describing gender-based differences in efficacy, safety, tolerability, pharmacokinetics, drug–drug interactions and adherence are critically evaluated.
Conclusions
As part of a combination antiretroviral therapy regimen, ATV/r appears to be a safe, effective and durable option for treatment-naive and early treatment-experienced patients with HIV-1 infection, including non-pregnant and pregnant women.
HodderS.L., JustmanJ., HughesJ.HIV incidence in women at risk for HIV acquisition in the United States: HPTN 064 (ISIS Study).19th Conference on Retroviruses and Opportunistic Infections. 5–8 March 2012, Seattle, WA, USA.
HodderS.L., JustmanJ., HaleyD.F.Challenges of a hidden epidemic: HIV prevention among women in the United States. J Acquir Immune Defic Syndr2010; 55: S69–S73.
8.
El-BasselN., CaldeiraN.A., RuglassL.M., GilbertL.Addressing the unique needs of African American women in HIV prevention. Am J Public Health2009; 99: 996–1001.
9.
World Health Organisation (WHO).Women and health: today's evidence tomorrow's agenda. (Updated 9 November 2009. Accessed 9 September 2013.) Available from http://www.who.int/gender/women_health_report/en/.
10.
JarrinI., GeskusR., BhaskaranK.Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. Am J Epidemiol2008; 168: 532–540.
11.
The HIV-CAUSAL Collaboration.The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS2010; 24: 123–137.
SoonG.G., MinM., StrubleK.A.Meta-analysis of gender differences in efficacy outcomes for HIV-positive subjects in randomized controlled clinical trials of antiretroviral therapy (2000-2008). AIDS Patient Care STDS2012; 26: 444–453.
14.
Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.Department of Health and Human Services. (Updated 12 February 2013. Accessed 6 September 2013.) Available from http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf.
15.
European AIDS Clinical Society.Guidelines version 6.1 -November 2012. (Updated November 2012. Accessed 1 April 2014.) Available from http://www.eacsociety.org/Guidelines.aspx.
16.
Gemeinsame Erklärung der Deutschen AIDS-Gesellschaft (DAIG) und der Österreichischen AIDS-Gesellschaft (ÖAG).[Antiretroviral therapy of HIV infection. German-Austrian guidelines (position in September 2008)]. Dtsch Med Wochenschr2009; 134: S4–15. German.
17.
CroomK.F., DhillonS., KeamS.J.Atazanavir: a review of its use in the management of HIV-1 infection. Drugs2009; 69: 1107–1140.
18.
ThompsonM.A., AbergJ.A., CahnP.Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA2010; 304: 321–333.
19.
CurrierJ., Averitt BridgeD., HaginsD.Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med2010; 153: 349–357.
20.
CampbellT.B., SmeatonL.M., KumarasamyN.Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings. PLoS Med2012; 9: e1001290.
21.
SquiresK.E., JohnsonM., YangR.Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study. J Antimicrob Chemother2011; 66: 363–370.
22.
SmithK., TierneyC., DaarE.Association of race/ ethnicity and sex on outcomes in ACTG Study A5202.18th Conference on Retroviruses and Opportunistic Infections. 27 February – 2 March, 2011, Boston, MA, USA. Abstract 536.
23.
Svedhem-JohanssonV., PuglieseP., BrockmeyerN.H.Long-term gender-based outcomes for atazanavir/ritonavir (ATV/r)-containing regimens in treatment-experienced patients with HIV. Curr HIV Res2013; 11: 333–341.
24.
KwakwaH., SpencerD., EvansC., GarnerW., WalkerI., TemmeL.Gender differences in virologic outcomes in a meta-analysis of randomized controlled clinical trials in HIV-1-infected patients on antiretroviral therapy.XIX International AIDS Conference. 22–27 July 2012, Washington, DC, USA. Abstract THPE041.
25.
SquiresK., YoungB., SantiagoL.Gender stratification analysis of HIV-1 infected patients receiving atazanavir (ATV) compared to ATV/ritonavir (RTV), each in combination with abacavir/lamivudine (ABC/3TC), after initial suppression with ABC/3TC + ATV/RTV through 144 weeks on therapy.52nd Interscience Conference on Antimicrobial Agents and Chemotherapy. 9–12 September, 2012, San Francisco, CA, USA. Abstract H-882.
26.
CuzinL., FlandreP., PuglieseP.Atazanavir in patients with persistent viral replication despite HAART: results from the French prospective NADIS cohort. HIV Clin Trials2008; 9: 147–151.
27.
MolinaJ.M., Andrade-VillanuevaJ., EchevarriaJ.Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet2008; 372: 646–655.
28.
MolinaJ.M., Andrade-VillanuevaJ., EchevarriaJ.Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr2010; 53: 323–332.
29.
DaarE.S., TierneyC., FischlM.A.Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med2011; 154: 445–456.
30.
DeJesusE., MillsA., BhattiL., ConnerC., StorferS.A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/ emtricitabine in treatment-naive patients. Int J Clin Pract2011; 65: 1240–1249.
31.
SmithK.Y., WeinbergW.G., DeJesusE.Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. AIDS Res Ther2008; 5: 5.
32.
JohnsonM., GrinsztejnB., RodriguezC.96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS2006; 20: 711–718.
33.
CalzaL., ManfrediR., ColangeliV.Efficacy and safety of atazanavir-ritonavir plus abacavir-lamivudine or tenofovir-emtricitabine in patients with hyperlipidaemia switched from a stable protease inhibitor-based regimen including one thymidine analogue. AIDS Patient Care STDS2009; 23: 691–697.
34.
JohnsonM., GrinsztejnB., RodriguezC.Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS2005; 19: 685–694.
35.
SorianoV., Garcia-GascoP., VispoE.Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. J Antimicrob Chemother2008; 61: 200–205.
36.
DeJesusE., RockstrohJ.K., HenryK.Week 48 results of an ongoing global Phase 3 study comparing elvitegravir/cobicistat/emtricitabine/tenofovir (Quad) with atazanavir/ritonavir plus emtricitabine/tenofovir in treatment-naive HIV-1+ subjects showing efficacy, safety, and pharmacokinetics.19th Conference on Retroviruses and Opportunistic Infections. 5– 8 March 2012, Seattle, WA, USA. Abstract 627.
37.
SquiresK.E., YoungB., DeJesusE.Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients. AIDS2010; 24: 2019–2027.
38.
SaxP.E., TierneyC., CollierA.C.Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med2009; 361: 2230–2240.
39.
SmithK.Y., TierneyC., MollanK.Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine. Clin Infect Dis2014; 58: 555–563.
40.
MannheimerS., FriedlandG., MattsJ., ChildC., ChesneyM.The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis2002; 34: 1115–1121.
41.
LiuH., MillerL.G., HaysR.D.Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors. J Acquir Immune Defic Syndr2006; 41: 315–322.
42.
VenutoC., MaQ., MollanK.Effect of sex and NRTI on atazanavir pharmacokinetics: ACTG Study A5202.19th Conference on Retroviruses and Opportunistic Infections. 5–8 March 2012, Seattle, WA, USA. Abstract 612.
43.
VenutoC., MollanK., MaQ.Atazanavir pharmacokinetics and efficacy and safety outcomes by sex in AIDS Clinical Trials Group Study 5202 (A5202).XIX International AIDS Conference. 22–27 July 2012, Washington DC, USA. Abstract TUPDB0101.
44.
PatelJ., LivakB., ColeJ.Efficacy and use of PI vs EFV in treatment naive HIV+ men and women.52nd Interscience Conference on Antimicrobials and Chemotherapy (ICAAC). 9–12 September 2012, San Francisco, CA, USA. Abstract H-883.
45.
AndradeA., BahetiG., SmeatonL.Sex- and geographic-based differences in ATV pharmacokinetics in subjects treated with ddI-EC, FTC, and ATV in the ACTG PEARLS Study.18th Conference on Retroviruses and Opportunistic Infections. 5 February–2 March 2011, Boston, MA, USA. Abstract 648.
46.
Cooper DA, Altair Study Group.Safety and efficacy of three different combination antiretroviral regimens as initial therapy for HIV infection: week 48 data from a randomised, open-label study.5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 19–22 July 2009, Cape Town, South Africa. Abstract LBPEB09.
47.
RubioR., SerranoO., CarmenaJ.Effect of simplification from protease inhibitors to boosted atazanavir-based regimens in real-life conditions. HIV Med2010; 11: 545–553.
48.
HayP., MoyleG., AndradeJ.Continuation of BID boosted PI vs switch to once-daily boosted atazanavir in subjects with lipohypertrophy. Final analysis of the 96-week multicentre, open-label, randomised prospective REAL study.15th Annual Conference of the British HIV Association. 1–3 April 2009, Liverpool, UK. Abstract 3.
49.
MallolasJ., PodzamczerD., MilinkovicA.Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study. J Acquir Immune Defic Syndr2009; 51: 29–36.
50.
GatellJ., Salmon-CeronD., LazzarinA.Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin Infect Dis2007; 44: 1484–1492.
51.
JansenK., SonnerborgA., BrockmeyerN.Long-term efficacy and safety of atazanavir/ritonavir treatment in a real-life cohort of treatment-experienced patients with HIV type 1 infection. AIDS Res Hum Retroviruses2013; 29: 564–573.
52.
HodderS., ArastehK., De WetJ.Effect of gender and race on the week 48 findings in treatment-naive, HIV-1-infected patients enrolled in the randomized, Phase III trials ECHO and THRIVE. HIV Med2012; 13: 406–415.
53.
LennoxJ.L., DeJesusE., BergerD.S.Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr2010; 55: 39–48.
54.
CohenC.J., MolinaJ.M., CahnP.Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the Phase 3 double-blind randomized ECHO and THRIVE trials. J Acquir Immune Defic Syndr2012; 60: 33–42.
55.
DeJesusE., CohenC., LennoxJ.Metabolic profiles and body composition changes in treatment-naive HIV-infected patients treated with raltegravir 400 mg bid-based vs. efavirenz 600 mg qhs-based combination therapy: 96-week follow-up.17th Conference on Retroviruses and Opportunistic Infections. 16–19 September 2010, San Francisco, CA, USA. Abstract 0-150.
56.
MurphyR.L., SanneI., CahnP.Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS2003; 17: 2603–2614.
57.
DoranD.A., JonesS.P., LagathuC.Mechanisms of insulin resistance in HIV-1-seronegative individuals acutely treated with ritonavir boosted indinavir and atazanavir regimens. Antivir Ther2004; 9: L6.
58.
NoorM.A., FlintO.P., MaaJ.F., ParkerR.A.Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS2006; 20: 1813–1821.
59.
NoorM.A., ParkerR.A., O'MaraE.The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS2004; 18: 2137–2144.
60.
JacksonA., PatelN., LoG., GazzardB., MoyleG.Effects of atazanavir or saquinavir once daily with ritonavir 100 mg and tenofovir/emtricitabine as initial therapy for HIV-1 infection on peripheral glucose disposal: a randomized open-label study.14th Conference on Retroviruses and Opportunistic Infections. 25–28 February 2007, Los Angeles, CA, USA. Abstract 818.
61.
McComseyG.A., KitchD., SaxP.E.Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. Clin Infect Dis2011; 53: 185–196.
62.
MoyleG.J., Andrade-VillanuevaJ., GirardP.M.A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity. Antivir Ther2012; 17: 689–700.
63.
MulliganK., HarrisD.R., MonteD.Obesity and dyslipidemia in behaviorally HIV-infected young women: Adolescent Trials Network study 021. Clin Infect Dis2010; 50: 106–114.
64.
NguyenA., CalmyA., SchifferV.Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006. HIV Med2008; 9: 142–150.
65.
StanleyT.L., JoyT., HadiganC.M.Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients. AIDS2009; 23: 1349–1357.
66.
McComseyG., RightmireA., WirtzV., YangR., MathewM., McGrathD.Changes in body composition with ritonavir-boosted and unboosted atazanavir treatment in combination with lamivudine and stavudine: a 96-week randomized, controlled study. Clin Infect Dis2009; 48: 1323–1326.
67.
LeroyerS., VatierC., KadiriS.Glyceroneogenesis is inhibited through HIV protease inhibitor-induced inflammation in human subcutaneous but not visceral adipose tissue. J Lipid Res2011; 52: 207–220.
68.
GalliM., VegliaF., AngaranoG.Gender differences in antiretroviral drug-related adipose tissue alterations. Women are at higher risk than men and develop particular lipodystrophy patterns. J Acquir Immune Defic Syndr2003; 34: 58–61.
69.
NasiM., PintiM., ChiesaE.Decreased mitochondrial DNA content in subcutaneous fat from HIV-infected women taking antiretroviral therapy as measured at delivery. Antivir Ther2011; 16: 365–372.
70.
MorrisA.A., CarrA.HIV nucleoside analogues: new adverse effects on mitochondria?Lancet1999; 354: 1046–1047.
71.
van der ValkM., CasulaM., WeverlingzG.J.Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy. Antivir Ther2004; 9: 385–393.
72.
CicconiP., BiniT., BarassiA.Detrimental effect of atazanavir plasma concentrations on total serum bilirubin levels in the presence of UGT1A1 polymorphisms. J Acquir Immune Defic Syndr2011; 56: e96–e97.
73.
ChoeP.G., ParkW.B., SongJ.S.Incidence of atazanavir-associated hyperbilirubinemia in Korean HIV patients: 30 months follow-up results in a population with low UDP-glucuronosyltransferase1A1*28 allele frequency. J Korean Med Sci2010; 25: 1427–1430.
74.
UyJ., HuW., WirtzV.Clinical significance of hyperbilirubinemia in the CASTLE study. J Int AIDS Soc2010; 13Suppl 4: P93.
75.
HardyH., EleyT., ChildM.J.The safety, efficacy, and steady state pharmacokinetics of atazanavir/ritonavir (ATV/r) once daily given in combination with twice daily AZT/3TC during pregnancy: results of study AI424182. Rev Antivir Ther Infect Dis2011; 1: 44 (P_18).
76.
BrownT.T., QaqishR.B.Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS2006; 20: 2165–2174.
77.
GallantJ.E., StaszewskiS., PozniakA.L.Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA2004; 292: 191–201.
78.
MoyleG., WardD., FarajallahA.Changes in bone mineral density after 96 weeks of treatment with tenofovir DF/emtricitabine plus atazanavir/ritonavir or lopinavir/ ritonavir in HIV-1 infected treatment naive subjects: the CASTLE body composition sub-study.6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 17–20 July 2011, Rome, Italy. Abstract TUPE244.
79.
McComseyG.A., KitchD., DaarE.S.Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis2011; 203: 1791–1801.
80.
von HentigN., BabacanE., LennemannT.The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors. J Antimicrob Chemother2008; 62: 579–582.
81.
Le TiecC., BarrailA., GoujardC., TaburetA.M.Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet2005; 44: 1035–1050.
82.
Swainston HarrisonT., ScottL.J.Atazanavir: a review of its use in the management of HIV infection. Drugs2005; 65: 2309–2336.
RipamontiD., CattaneoD., AiroldiM.Atazanavir-based HAART in pregnancy.14th Conference on Retroviruses and Opportunistic Infections. 25–28 February 2007, Los Angeles, CA, USA. Abstract 742.
85.
ConradieF., ZorrillaC., JosipovicD.Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women. HIV Med2011; 12: 570–579.
86.
EleyT., VandeloiseE., ChildM.Steady state pharmacokinetics and safety of atazanavir after treatment with ATV 300 mg once daily/ritonavir 100 mg once daily+ZDV/3TC during the third trimester in HIV+women.15th Conference on Retroviruses and Opportunistic Infections. 3–6 February 2008, Boston, MA, USA. Abstract 624.
87.
RipamontiD., CattaneoD., D'AvolioA.Steady state pharmacokinetics of ritonavir-boosted atazanavir in 31 pregnant women before and after delivery.17th Conference on Retroviruses and Opportunistic Infections. 16–19 February 2010, San Francisco, CA, USA. Abstract 907.
88.
MirochnickM., BestB.M., StekA.M.Atazanavir pharmacokinetics with and without tenofovir during pregnancy. J Acquir Immune Defic Syndr2011; 56: 412–419.
89.
WalduraJ.F.Prevention of perinatal HIV transmission: the Perinatal HIV Hotline perspective. Top Antivir Med2011; 19: 23–26.
90.
ElseL.J., JacksonV., BrennanM.Therapeutic drug monitoring (TDM) of atazanavir in pregnancy. J Int AIDS Soc2010; 13Suppl 4: P177.
91.
SchwartzS.R., ReesH., MehtaS., VenterW.D., TahaT.E., BlackV.High incidence of unplanned pregnancy after antiretroviral therapy initiation: findings from a prospective cohort study in South Africa. PLoS ONE2012; 7: e36039.
92.
RipamontiD., CattaneoD., MaggioloF.Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS2007; 21: 2409–2415.
Antiretroviral Pregnancy Registry Steering Committee.Antiretroviral pregnancy registry international interim report for 1 January 1989 through 31 January 2013. (Updated June 2013. Accessed 6 September 2013.) Available from http://www.apregistry.com/forms/interim_report.pdf.
95.
ZhangJ., ChungE., YonesC.The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women. Antivir Ther2011; 16: 157–164.
96.
PuskasC.M., ForrestJ.I., ParasharS.Women and vulnerability to HAART non-adherence: a literature review of treatment adherence by gender from 2000 to 2011. Curr HIV/AIDS Rep2011; 8: 277–287.
97.
OrtegoC., Huedo-MedinaT.B., SantosP.Sex differences in adherence to highly active antiretroviral therapy: a meta-analysis. AIDS Care2012; 24: 1519–1534.
98.
TouloumiG., PantazisN., AntoniouA.Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences. J Acquir Immune Defic Syndr2006; 42: 554–561.
99.
MaggioloF., LeoneS., CologniG., ValentiD., QuinzanG., SuterF.Persistence on first line HAART is influenced by dosing schedule.18th International AIDS Society World AIDS Conference. 18–23 July 2010, Vienna, Austria. Abstract TUPE0178.
100.
MooreA.L., KirkO., JohnsonA.M.Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J Acquir Immune Defic Syndr2003; 32: 452–461.
101.
WalmsleyS.L., SquiresK., WeissL.Multidrug-experienced HIV-1-infected women demonstrated similar virological and immunological responses to tipranavir/ritonavir compared with men. AIDS2009; 23: 429–431.
102.
FourieJ., FlammJ., Rodriguez-FrenchA.Effect of baseline characteristics on the efficacy and safety of once-daily darunavir/ ritonavir in HIV-1-infected, treatment-naive ARTEMIS patients at week 96. HIV Clin Trials2011; 12: 313–322.
103.
AbsalanJ., UyJ., YangR.Gender-based differences in ARV-naive patients treated with boosted protease inhibitors: results from the CASTLE study (AI424138).17th International AIDS Conference. 3–8 August 2008, Mexico City, Mexico.
104.
GrinsztejnB., SmeatonL., BarnettR.Sex-associated differences in pre-antiretroviral therapy plasma HIV-1 RNA in diverse areas of the world vary by CD4(+) T-cell count. Antivir Ther2011; 16: 1057–1062.
105.
UmehO.C., CurrierJ.S., ParkJ.G., CramerY., HermesA.E., FletcherC.V.Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men. J Clin Pharmacol2011; 51: 1665–1673.
106.
ClumeckN., PozniakA., RaffF.European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med2008; 9: 65–71.
107.
GazzardB.G.British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med2008; 9: 563–608.
